Login to Your Account

Clinic Roundup

Thursday, August 1, 2013
• Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, opened its third clinical trial site at the Brain Tumor Center at University of California, San Francisco. Delmar is conducting a Phase I/II dose-escalation study designed to assess the safety and activity of VAL-083 as a potential treatment for brain cancer patients suffering from glioblastoma multiforme (GBM) who have failed standard therapies and have no viable treatment options.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription